Meds & supplements › Norelgestromin
Medicine · Progestin
Norelgestromin and ethinyl estradiol transdermal system is indicated for the prevention of pregnancy in women with a body mass index (BMI) < 30 kg/m 2 for whom a combined hormonal contraceptive is appropriate.
Selected manufacturer label information, organised into consistent sections by Sofidex. Read the full label at DailyMed ↗
Norelgestromin and ethinyl estradiol transdermal system is a birth control patch for women with a BMI less than 30 kg/m 2. It contains two female hormones, an estrogen called ethinyl estradiol, and a progestin called norelgestromin.
Hormones from norelgestromin and ethinyl estradiol transdermal system get into the blood stream and are processed by the body differently than hormones from birth control pills. You will be exposed to about 60% more estrogen if you use norelgestromin and ethinyl estradiol transdermal system than if you use a typical birth control pill containing 35 micrograms of estrogen. In general, increased estrogen may increase the risk of side effects.
When you use norelgestromin and ethinyl estradiol transdermal system you may have bleeding and spotting between periods, called unplanned bleeding. Unplanned bleeding may vary from slight staining between menstrual periods to breakthrough bleeding which is a flow much like a regular period. Unplanned bleeding occurs most often during the first few months of norelgestromin and ethinyl estradiol transdermal system use, but may also occur after you have been using the patch for some time. Such bleeding may be temporary and usually does not indicate any serious problems. It is important to continue using the patch on schedule. If the unplanned bleeding or spotting is heavy or lasts for more than a few days, you should discuss this with your healthcare provider.
Some women miss periods on hormonal birth control, even when they are not pregnant. However, if you go 2 or more months in a row without a period, or you miss your period after a month where you did not use all of your patches correctly, or you have symptoms associated with pregnancy, such as morning sickness or unusual breast tenderness, call your healthcare provider because you may be pregnant. Stop taking norelgestromin and ethinyl estradiol transdermal system if you are pregnant.
Norelgestromin and ethinyl estradiol transdermal system may cause serious side effects, including:
To put the risk of developing a blood clot into perspective: If 10,000 women who are not pregnant and do not use hormonal birth control are followed for one year, between 1 and 5 of these women will develop a blood clot. The figure below shows the likelihood of developing a serious blood clot for women who are not pregnant and do not use hormonal birth control, for women who use hormonal birth control, for pregnant women, and for women in the first 12 weeks after delivering a baby.
Likelihood of Developing a Serious Blood Clot (Venous Thromboembolism [VTE])
*CHC=combination hormonal contraception
**Pregnancy data based on actual duration of pregnancy in the reference studies. Based on a model assumption that pregnancy duration is nine months, the rate is 7 to 27 per 10,000 WY.
Call your healthcare provider right away if you have:
Other serious risks include
The most common side effects of norelgestromin and ethinyl estradiol transdermal system are:
Some women have spotting or light bleeding, breast tenderness, or feel sick to their stomach during norelgestromin and ethinyl estradiol transdermal system use. If these symptoms occur, do not stop using the norelgestromin and ethinyl estradiol transdermal patch. The problem will usually go away. If it does not go away, check with your healthcare provider.
Less common side effects are:
Tell your healthcare provider about any side effect that bothers you or that does not go away.
These are not all the possible side effects of norelgestromin and ethinyl estradiol transdermal system. For more information, ask your healthcare provider or pharmacist.
Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
You may stop using norelgestromin and ethinyl estradiol transdermal system whenever you wish. Consider a visit with your healthcare provider for a pre-pregnancy checkup before you stop using the patch.
Distributed by: Amneal Pharmaceuticals LLC Bridgewater, NJ 08807
Rev. 03-2022-02
Keep norelgestromin and ethinyl estradiol transdermal system and all medicines out of the reach of children.
General information about the safe and effective use of norelgestromin and ethinyl estradiol transdermal system
Medicines are sometimes prescribed for purposes other than those listed in Patient Information. Do not use norelgestromin and ethinyl estradiol transdermal system for a condition for which it was not prescribed. Do not give norelgestromin and ethinyl estradiol transdermal system to other people, even if they have the same symptoms that you have. It may harm them.
You can ask your pharmacist or healthcare provider for information about norelgestromin and ethinyl estradiol transdermal system that is written for health professionals.
For more information, go to www.amneal.com or call 1-877-835-5472.
Your chance of getting pregnant depends on how well you follow the directions for using norelgestromin and ethinyl estradiol transdermal system. The better you follow the directions, the less chance you have of getting pregnant.
In clinical studies, 1 to 2 out of 100 women got pregnant during the first year that they used the norelgestromin and ethinyl estradiol transdermal system.
Norelgestromin and ethinyl estradiol transdermal system may not be as effective in women weighing more than 198 lbs. (90 kg). If you weigh more than 198 lbs. (90 kg), talk to your healthcare provider about which method of birth control is right for you.
The following chart shows the chance of getting pregnant for women who use different methods of birth control. Each box on the chart contains a list of birth control methods that are similar in effectiveness. The most effective methods are at the top of the chart. The box on the bottom of the chart shows the chance of getting pregnant for women who do not use birth control and are trying to get pregnant.
Do not use norelgestromin and ethinyl estradiol transdermal system if you:
Hormonal birth control methods may not be a good choice for you if you have ever had jaundice (yellowing of the skin or eyes) caused by pregnancy or related to previous use of hormonal birth control.
Tell your healthcare provider if you have ever had any of the above conditions. Your healthcare provider may recommend another method of birth control.
Before you use norelgestromin and ethinyl estradiol transdermal system, tell your healthcare provider:
Tell your healthcare provider about all medicines and herbal products that you take.
Some medicines and herbal products may make hormonal birth control less effective, including, but not limited to:
Use another birth control method (such as a condom and spermicide or diaphragm and spermicide) when you take medicines that may make the norelgestromin and ethinyl estradiol transdermal patch less effective.
Some medicines and grapefruit juice may increase your level of the hormone ethinyl estradiol if used together, including:
Hormonal birth control methods may interact with lamotrigine, an anti-seizure medicine used for epilepsy. This may increase the risk of seizures, so your healthcare provider may need to adjust the dose of lamotrigine.
Women on thyroid replacement therapy may need increased doses of thyroid hormone.
Know the medicines you take. Keep a list of them to show your doctor and pharmacist when you get a new medicine.
sofidex [Internet]. Daloreum; c2026. Norelgestromin; [reviewed 2026 Aug 3; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/norelgestromin
sofidex. (2026, August 3). Norelgestromin. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/norelgestromin
Norelgestromin. sofidex. Reviewed August 3, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/norelgestromin
The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.